Dualitas Therapeutics
PrivateLast Round
Series A
Sep 16, 2025
Total Funding Raised
$65M
Company Overview
Dualitas Therapeutics, Inc. is a biotechnology company that develops next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I). The company was founded in 2023 and launched from stealth in September 2025 with a $65 million Series A financing. Dualitas utilizes its proprietary DualScreen™ discovery engine, which operates at a combinatorial scale to identify novel bispecific antibody candidates with highly differentiated activity. Its lead pipeline programs include DTX-103 for allergic diseases and DTX-102 for autoimmune diseases, which have shown compelling preclinical data compared to existing therapies. The company is backed by prominent venture capital firms and strategic investors, including Versant Ventures, Qiming Venture Partners USA, SV Health Investors, Eli Lilly and Company, and the Chugai Venture Fund.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dualitas Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Dualitas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 16, 2025 |
Dualitas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series A |
| Chugai Venture Fund | Series A |
| Versant Ventures | Series A |
| Alexandria Venture Investments | Series A |
Dualitas Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Dualitas Therapeutics's valuation, stock price, and market status.
